Success is hard to come by in drug development. “On average, 50% of phase III trials with novel therapeutics fail,” says Subha Madhavan, vice president and head of AI/ML at Pfizer. “A primary reason ...

Vol. 38, No. 3, Special Issue: Analysis of Covariance (Sep., 1982), pp. 651-660 (10 pages) When a treatment influences both the primary response and the covariate, a standard analysis of covariance ...

Testing for associations in big data faces the problem of multiple comparisons, wherein true signals are difficult to detect on the background of all associations queried. This difficulty is ...

This is a preview. Log in through your library . Abstract We consider two-armed clinical trials in which the response and/or the covariates are observed on either a binary, ordinal, or continuous ...